JRJamie L. Redes

Jamie L. Redes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jamie L. Redes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Albert C. Sek

    Inflammation Immunobiology Section, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland, USA

    1 shared publication
  • Chandra C. Ghosh

    Center for Vascular Biology Research, Department of Emergency Medicine, Beth Israel Deaconess Medical Center , Boston, MA 02215

    1 shared publication
  • Erik P. Karmele

    Immunopathogenesis Section, Laboratory of Parasitic Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda MD USA

    1 shared publication
  • Eunice C. Chan

    Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases/National Institutes of Health , Bethesda, MD 20892

    1 shared publication
  • Helene F. Rosenberg

    Inflammation Immunobiology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases/National Institutes of Health , Bethesda, MD 20892

    1 shared publication
  • Joshua C. Sciurba

    Affiliation Laboratory of Parasitic Diseases, NIAID, National Institutes of Health; Bethesda, Maryland, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Aspergillus fumigatus–Secreted Alkaline Protease 1 Mediates Airways Hyperresponsiveness in Severe Asthma

    by Jamie L. Redes, Trisha Basu, Sumati Ram-Mohan, Chandra C. Ghosh, Eunice C. Chan, Albert C. Sek, Ming Zhao, Ramaswamy Krishnan, Helene F. Rosenberg, Kirk M. Druey

    The hallmark features of allergic asthma are type 2 (eosinophilic) inflammation and airways hyperresponsiveness (AHR). Although these features often comanifest in mouse lungs in vivo, we demonstrate in this study that the serine protease Alp1 from the ubiquitous mold and allergen, Aspergillus fumigatus, can induce AHR in mice unable to generate eosinophilic inflammation. Strikingly, Alp1 induced AHR in mice devoid of protease-activated receptor 2/F2 trypsin-like receptor 1 (PAR2/F2RL1), a receptor expressed in lung epithelium that is critical for allergic responses to protease-containing allergens. Instead, using precision-cut lung slices and human airway smooth muscle cells, we demonstrate that Alp1 directly increased contractile force. Taken together, these findings suggest that Alp1 induces bronchoconstriction through mechanisms that are largely independent of allergic inflammation and point to a new target for direct intervention of fungal-associated asthma.


  • Open Access

    Fibroblast‐specific integrin‐alpha V differentially regulates type 17 and type 2 driven inflammation and fibrosis

    by Joshua C. Sciurba, Richard L Gieseck, Nikhil Jiwrajka, Sandra D. White, Erik P. Karmele, Jamie Redes, Kevin M. Vannella, Neil C. Henderson, Thomas A Wynn, Kevin M. Hart

    Fibroproliferative diseases affect a significant proportion of the world's population. Despite this, core mechanisms driving organ fibrosis of diverse etiologies remain ill defined. Recent studies suggest that integrin‐alpha V serves as a master driver of fibrosis in multiple organs. Although diverse mechanisms contribute to the progression of fibrosis, TGF‐β and IL‐13 have emerged as central mediators of fibrosis during type 1/type 17, and type 2 polarized inflammatory responses, respectively. To investigate if integrin‐alpha V interactions or signaling is critical to the development of type 2 fibrosis, we analyzed fibroblast‐specific integrin‐alpha V knockout mice in three type 2‐driven inflammatory disease models. While we confirmed a role for integrin‐alpha V in type 17‐associated fibrosis, integrin‐alpha V was not critical to the development of type 2‐driven fibrosis. Additionally, our studies support a novel mechanism through which fibroblasts, via integrin‐alpha V expression, are capable of regulating immune polarization. We show that when integrin‐alpha V is deleted on fibroblasts, initiation of type 17 inflammation is inhibited leading to a deregulation of type 2 inflammation. This mechanism is most evident in a model of severe asthma, which is characterized by a mixed type 2/type 17 inflammatory response. Together, these findings suggest dual targeting of integrin‐alpha V and type 2 pathways may be needed to ameliorate fibrosis and prevent rebound of opposing pro‐fibrotic and inflammatory mechanisms. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.